Parabilis Medicines, Inc. (Ticker: PBLS) is an emerging company at the forefront of the telecommunications sector, dedicated to delivering innovative communication solutions tailored for both residential and commercial markets. The company leverages advanced technologies to enhance connectivity and customer experiences, positioning itself strategically for growth in the rapidly evolving digital landscape. With a strong focus on expanding its infrastructure and maintaining operational excellence, PBLS represents a compelling investment opportunity for institutional investors seeking to capitalize on the burgeoning demand for seamless communication services.
| Revenue (TTM) | 148,000 |
| Gross Profit (TTM) | $-12.95M |
| EBITDA | $-169.11M |
| Operating Margin | -34382.00% |
| Return on Equity | 0.00% |
| Return on Assets | 0.00% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $8.48 |
| Price-to-Book | 4.34 |
| Price-to-Sales (TTM) | 21017.34 |
| EV/Revenue | 23498.51 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $121.95M |
| Float | $82.07M |
| % Insiders | 7.03% |
| % Institutions | 82.45% |
Volatility is currently contracting
New dose-ranging cohort in FAP builds on compelling early clinical evidence observed with zolucatetide in patients with FAP and concomitant desmoid tumors
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced its Chairman, President and Chief Executive Officer Mathai Mammen, M.D.
CAMBRIDGE, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced the appointment of Craig L.
Parabilis Medicines (PBLS) leverages rare, genetically simple tumors to validate its Helicon platform, aiming for broader oncology applications. PBLS holds $1.1 billion in cash, providing a runway into 2030 to support clinical trials, platform expansion, and reduce financing risk. Early zolucatetide data in desmoid tumors show 100% tumor reduction and 74% objective response, with a favorable safety profile versus competitors.
Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
CAMBRIDGE, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease, today announced the closing of its upsized initial public offering of an aggregate 38,525,000 shares of its common stock, including the full exercise by the underwriters of their overallotment option to purchase 5,025,000 additional shares, at an initial public offering price of $20.00 per share. All of the shares of common stock were offered by Parabilis. Parabilis' common stock began trading on the Nasdaq Global Select Market on June 10, 2026 under the ticker symbol “PBLS”.
CAMBRIDGE, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease, today announced the pricing of its upsized initial public offering of 33,500,000 shares of its common stock at a price to the public of $20.00 per share. In addition, Parabilis has granted the underwriters a 30-day option to buy an additional 5,025,000 shares of its common stock at the initial public offering price, less underwriting discounts and commissions.
Biopharmaceutical company Parabilis Medicines said on Tuesday it was aiming to raise as much as $633.3 million in its upsized initial public offering in the U.S.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PBLS and any ticker you trade — then tracks every position and per-strategy win rate.
